Evidence map›Paper›PMID 38072913›Full record

ArticleDaru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences2024

Multi-functionalization of reduced graphene oxide nanosheets for tumor theragnosis: Synthesis, characterization, enzyme assay, in-silico study, radiolabeling and in vivo targeting evaluation.

Tamer M Sakr, Mohammed F Elsabagh, Hend Fayez, Mona O Sarhan, Yasmin M Syam, Manal M Anwar, Mohammed A Motaleb, Wafaa A Zaghary

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tamer M SakrRadioisotopes Production Facility, Second Egyptian Research Reactor Complex, Egyptian Atomic Energy Authority, Cairo, 13759, Egypt.
Mohammed F ElsabaghRadioisotopes Production Facility, Second Egyptian Research Reactor Complex, Egyptian Atomic Energy Authority, Cairo, 13759, Egypt. mohamed.elsabagh@eaea.sci.eg.ORCID http://orcid.org/0000-0002-6145-0975
Hend FayezLabeled Compounds Department, Hot Labs Center, Egyptian Atomic Energy Authority, Cairo, 13759, Egypt.
Mona O SarhanLabeled Compounds Department, Hot Labs Center, Egyptian Atomic Energy Authority, Cairo, 13759, Egypt.
Yasmin M SyamDepartment of Therapeutic Chemistry/ National Research Centre, Cairo, Egypt.
Manal M AnwarDepartment of Therapeutic Chemistry/ National Research Centre, Cairo, Egypt.
Mohammed A MotalebLabeled Compounds Department, Hot Labs Center, Egyptian Atomic Energy Authority, Cairo, 13759, Egypt.
Wafaa A ZagharyDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Helwan University, Cairo, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn this study, a combination of nanotechnology, organic synthesis and radiochemistry were utilized in order to design an efficient nano-system conjugated with a suitable radionuclide and an antitumor agent for possible application as tumor theragnostic agent.

methodFour novel compounds (3 and 4a-c) bearing tetrahydroquinazoline-7-sulfonohydrazide or 1,2,3,4-tetrahydroquinazoline-7-sulfonamide scaffold were designed. Then, docking study predicted that the compounds can be considered as potential inhibitors for PARP-1. Following that; the four compounds were synthesized and properly characterized using

resultCarboxylated graphene oxide nanosheets (NGO-COOH) were synthesized by a modified Hummer's method and has size of range 40 nm. The NGO-COOH nanosheets were proven to be safe and biocompatible when tested in vitro against normal human lung fibroblast cells (MRC-5). The prepared NGO-COOH nanosheets were conjugated with compound 3 then radiolabeled with

conclusionStirred a new candidate tumor theragnostic agent that is safe, selective and stable.

Indexed as

GraphiteAnimalsAntineoplastic AgentsBreast NeoplasmsCell Line, TumorFemaleHumansMiceMolecular Docking SimulationNanostructuresPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase InhibitorsTissue DistributionAntineoplastic Agentsgraphene oxideGraphitePARP1 protein, humanPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase InhibitorsActive targetingIn-silico studyNanographene sheetsNano synthesisPRAP-1 inhibitorRadiolabelingTechnetium-99mTumor imagingTumor theragnosis

Identifiers

PMID38072913
PMCPMC11087444

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.